SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

HUTCHMED Highlights Phase III SANOVO Trial Data in China

Phase III SANOVO in China showed ORPATHYS plus TAGRISSO significantly improved progression-free survival.

AZNHCM

Related stories